Inflammatory Mediators in Kidney Disease: A Focus on IL-6in SLE-Associated CKD
DOI:
https://doi.org/10.61882/ijkd.19.04.8861Keywords:
Chronic kidney disease, Lupus erythematosus, Systemic, Lupus nephritis, Interleukin-6, Tumor necrosis factor-alphaAbstract
Introduction. Systemic lupus erythematosus (SLE) is an autoimmune condition that can lead to severe renal impairment, including chronic kidney disease (CKD) or end-stage kidney disease (ESKD). This study aimed to evaluate the serum levels of key pro-inflammatory cytokines which are well-known to mediate tissue injury and fibrosis in the context of kidney diseases—interleukin-1 beta (IL-1β), IL-6, tumor necrosis factor-alpha (TNF-α), and IL-12—in CKD and ESKD patients with and without SLE, as well as in healthy controls, to explore their role in disease progression.
Methods. This cross-sectional study was conducted over a 15-month period in three governmental medical centers of Golestan Province, Iran (Sayyad Shirazi Hospital, 5th Azar hospital, and Al-Jalil hospital). A total of 118 individuals (age 18-65 years) were enrolled and divided into three groups:38 CKD or ESKD patients with SLE, 40 CKD or ESKD patients without SLE, and 40 healthy controls. For subgroup analyses, CKD (stages3-4) and ESKD (stage 5) patients were considered separately. Those patients meeting the American College of Rheumatology criteria for SLE, while excluding those with infections, malignancies, or other autoimmune disorders were selected. Blood samples were collected, and serum cytokine levels were measured using enzyme-linked immunosorbent assay (ELISA). Statistical analysis was performed using the Kruskal-Wallis and Mann-Whitney U tests, with P ≤ .05 considered significant.
Results. CKD patients with SLE showed significantly higher serum levels of IL-1β, TNF-α, and IL-12 compared to CKD patients without SLE and healthy controls (P < .05). IL-6 levels were notably higher in CKD patients compared to ESKD patients, irrespective of SLE status (P < .05). ESKD patients exhibited increased IL-1β, TNF-α, and IL-12 levels, while IL-6 levels were lower than those in CKD patients.
Conclusion. IL-6 appears to play a crucial role in the pathogenesis of kidney disease, particularly in patients with SLE, and may serve as a therapeutic target. The differential regulation of cytokines in CKD and ESKD suggests that inflammatory pathways vary based on disease stage and the presence of SLE.
Downloads
References
1. Chen TK, Knicely DH and Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. Jama 2019; 322: 1294-1304. DOI: 10.1001/jama.2019.14745.
2. Rathgeber SL, Lam C, Harris KC and Grewal J. Hepatic and Renal Consequences of Single-Ventricle Physiology Palliated With the Fontan Operation. Can J Cardiol 2022; 38: 1002-1011. 20220504. DOI: 10.1016/j.cjca.2022.04.022.
3. Kellum JA, Romagnani P, Ashuntantang G, et al. Acute kidney injury. Nature Reviews Disease Primers 2021; 7: 52. DOI: 10.1038/s41572-021-00284-z.
4. Santos M, Yin H, Steffick D, et al. Predictors of kidney function recovery among incident ESRD patients. BMC Nephrology 2021; 22: 142. DOI: 10.1186/s12882-021-02345-7.
5. Major RW, Cheng MRI, Grant RA, et al. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. PLoS One 2018; 13: e0192895. 20180321. DOI: 10.1371/journal.pone.0192895.
6. Ameer MA, Chaudhry H, Mushtaq J, et al. An Overview of Systemic Lupus Erythematosus (SLE) Pathogenesis, Classification, and Management. Cureus 2022; 14: e30330. 20221015. DOI: 10.7759/cureus.30330.
7. Weckerle CE and Niewold TB. The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies. Clin Rev Allergy Immunol 2011; 40: 42-49. DOI: 10.1007/s12016-009-8192-4.
8. Cojocaru M, Cojocaru IM, Silosi I and Vrabie CD. Manifestations of systemic lupus erythematosus. Maedica (Bucur) 2011; 6: 330-336.
9. Parodis I, Tamirou F and Houssiau FA. Prediction of prognosis and renal outcome in lupus nephritis. Lupus Sci Med 2020; 7: e000389. 20200218. DOI: 10.1136/lupus-2020-000389.
10. Moschetti L, Piantoni S, Vizzardi E, et al. Endothelial Dysfunction in Systemic Lupus Erythematosus and Systemic Sclerosis: A Common Trigger for Different Microvascular Diseases. Front Med (Lausanne) 2022; 9: 849086. 20220408. DOI: 10.3389/fmed.2022.849086.
11. Gyurászová M, Gurecká R, Bábíčková J and Tóthová Ľ. Oxidative Stress in the Pathophysiology of Kidney Disease: Implications for Noninvasive Monitoring and Identification of Biomarkers. Oxid Med Cell Longev 2020; 2020: 5478708. 20200123. DOI: 10.1155/2020/5478708.
12. Chen L, Deng H, Cui H, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 2018; 9: 7204-7218. 20171214. DOI: 10.18632/oncotarget.23208.
13. Ohl K and Tenbrock K. Inflammatory cytokines in systemic lupus erythematosus. J Biomed Biotechnol 2011; 2011: 432595. 20111016. DOI: 10.1155/2011/432595.
14. Yuan Q, Tang B and Zhang C. Signaling pathways of chronic kidney diseases, implications for therapeutics. Signal Transduction and Targeted Therapy 2022; 7: 182. DOI: 10.1038/s41392-022-01036-5.
15. Mary KC. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Annals of the Rheumatic Diseases 2023; 82: 999. DOI: 10.1136/ard-2022-223741.
16. Mende R, Vincent FB, Kandane-Rathnayake R, et al. Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus. Front Immunol 2018; 9: 1250. 20180607. DOI: 10.3389/fimmu.2018.01250.
17. Umare V, Pradhan V, Nadkar M, et al. Effect of Proinflammatory Cytokines (IL-6, TNF-α, and IL-1β) on Clinical Manifestations in Indian SLE Patients. Mediators of Inflammation 2014; 2014: 385297. DOI: 10.1155/2014/385297.
18. Zhan Y, Cheng L, Wu B, et al. Interleukin (IL)-1 family cytokines could differentiate primary immune thrombocytopenia from systemic lupus erythematosus-associated thrombocytopenia. Annals of Translational Medicine 2021; 9: 222.
19. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 2019; 71: 1400-1412. 20190806. DOI: 10.1002/art.40930.
20. Italiani P, Manca ML, Angelotti F, et al. IL-1 family cytokines and soluble receptors in systemic lupus erythematosus. Arthritis Res Ther 2018; 20: 27. 20180208. DOI: 10.1186/s13075-018-1525-z.
21. Rashad NM, Soliman MH, El-Shal AS, et al. Effect of interleukin-1β gene polymorphisms on clinicopathological features and disease activity of systemic lupus erythematosus. The Egyptian Journal of Internal Medicine 2019; 31: 235-242. DOI: 10.4103/ejim.ejim_92_18.
22. Wu Y, Cai B, Zhang J, et al. IL-1β and IL-6 Are Highly Expressed in RF+IgE+ Systemic Lupus Erythematous Subtype. J Immunol Res 2017; 2017: 5096741. 20170212. DOI: 10.1155/2017/5096741.
23. Ripley BJM, Goncalves B, Isenberg DA, et al. Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Annals of the Rheumatic Diseases 2005; 64: 849-853. DOI: 10.1136/ard.2004.022681.
24. Ruchakorn N, Ngamjanyaporn P, Suangtamai T, et al. Performance of cytokine models in predicting SLE activity. Arthritis Research & Therapy 2019; 21: 287. DOI: 10.1186/s13075-019-2029-1.
25. Hsu H-C, Chen Y-H, Lin T-S, et al. Systemic lupus erythematosus is associated with impaired autophagic degradation via interleukin-6 in macrophages. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2021; 1867: 166027.
26. Ding J, Su S, You T, et al. Serum interleukin-6 level is correlated with the disease activity of systemic lupus erythematosus: a meta-analysis. Clinics (Sao Paulo) 2020; 75: e1801. 20201019. DOI: 10.6061/clinics/2020/e1801.
27. Liu TF, Jones BM, Wong RWS and Srivastava G. IMPAIRED PRODUCTION OF IL-12 IN SYSTEMIC LUPUS ERYTHEMATOSUS. III: DEFICIENT IL-12p40 GENE EXPRESSION AND CROSS-REGULATION OF IL-12, IL-10 AND IFN-γ GENE EXPRESSION. Cytokine 1999; 11: 805-811.
28. Liu TF and Jones BM. IMPAIRED PRODUCTION OF IL-12 IN SYSTEM LUPUS ERYTHEMATOSUS. II: IL-12 PRODUCTION IN VITRO IS CORRELATED NEGATIVELY WITH SERUM IL-10, POSITIVELY WITH SERUM IFN-γ AND NEGATIVELY WITH DISEASE ACTIVITY IN SLE. Cytokine 1998; 10: 148-153.
29. Tokano Y, Morimoto S, Kaneko H, et al. Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE)--relation to Th1- and Th2-derived cytokines. Clin Exp Immunol 1999; 116: 169-173. DOI: 10.1046/j.1365-2249.1999.00862.x.
30. Li L, Sun X, Wu S, et al. Interleukin-12 exacerbates symptoms in an MRL/MpJ-Faslpr mouse model of systemic lupus erythematosus. Exp Ther Med 2021; 21: 627. 20210415. DOI: 10.3892/etm.2021.10059.
31. Jones SA, Fraser DJ, Fielding CA and Jones GW. Interleukin-6 in renal disease and therapy. Nephrology Dialysis Transplantation 2014; 30: 564-574. DOI: 10.1093/ndt/gfu233.
32. Balasubbramanian D, Goodlett BL and Mitchell BM. Is IL-12 pro-inflammatory or anti-inflammatory? Depends on the blood pressure. Cardiovascular Research 2019; 115: 998-999. DOI: 10.1093/cvr/cvz028.
33. Chang HD and Radbruch A. The pro- and anti-inflammatory potential of interleukin-12. Ann N Y Acad Sci 2007; 1109: 40-46. DOI: 10.1196/annals.1398.006.
34. Chang HD and Radbruch A. The pro- and anti-inflammatory potential of IL-12: the dual role of Th1 cells. Expert Rev Clin Immunol 2007; 3: 709-719. DOI: 10.1586/1744666x.3.5.709.
35. Cobo G, Lindholm B and Stenvinkel P. Chronic inflammation in end-stage renal disease and dialysis. Nephrol Dial Transplant 2018; 33: iii35-iii40. DOI: 10.1093/ndt/gfy175.
36. Lisowska KA, Storoniak H and Dębska-Ślizień A. T cell subpopulations and cytokine levels in hemodialysis patients. Human Immunology 2022; 83: 134-143.
37. Batra G, Ghukasyan Lakic T, Lindbäck J, et al. Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. JAMA Cardiol 2021; 6: 1440-1445. DOI: 10.1001/jamacardio.2021.3079.
38. Perlman AS, Chevalier JM, Wilkinson P, et al. Serum Inflammatory and Immune Mediators Are Elevated in Early Stage Diabetic Nephropathy. Annals of Clinical & Laboratory Science 2015; 45: 256-263.
39. Steensberg A, Fischer CP, Keller C, et al. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. American Journal of Physiology-Endocrinology and Metabolism 2003; 285: E433-E437.
40. Kitani A, Hara M, Hirose T, et al. Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression. Clinical & Experimental Immunology 1992; 88: 75-83.
41. Yoshimura A, Suzuki M, Sakaguchi R, et al. SOCS, inflammation, and autoimmunity. Frontiers in immunology 2012; 3: 20.
42. Wiegertjes R, Van Caam A, Van Beuningen H, et al. TGF-β dampens IL-6 signaling in articular chondrocytes by decreasing IL-6 receptor expression. Osteoarthritis and cartilage 2019; 27: 1197-1207.
43. Williams LM, Ricchetti G, Sarma U, et al. Interleukin‐10 suppression of myeloid cell activation—a continuing puzzle. Immunology 2004; 113: 281-292.
44. Kir HM, Eraldemir C, Dervisoglu E, et al. Effects of chronic kidney disease and type of dialysis on serum levels of adiponectin, TNF-alpha and high sensitive C-reactive protein. Clin Lab 2012; 58: 495-500.
45. Zein HS, Abou-Samra E, Scur M, et al. Clr-f expression regulates kidney immune and metabolic homeostasis. Scientific Reports 2022; 12: 4834.
46. Soria-Artzi G, Ofri-Shahak M, Haas I, et al. Inflammatory mediators in breast cancer: Coordinated expression of TNF?? & IL-1?? with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC cancer 2011; 11: 130. DOI: 10.1186/1471-2407-11-130.
47. Ajoy R, Lo Y-C, Ho M-H, et al. CCL5 promotion of bioenergy metabolism is crucial for hippocampal synapse complex and memory formation. Molecular Psychiatry 2021; 26: 6451-6468. DOI: 10.1038/s41380-021-01103-3.
48. Gu Y-Y, Liu X-S, Huang X-R, et al. Diverse Role of TGF-β in Kidney Disease. Frontiers in Cell and Developmental Biology 2020; 8. Review. DOI: 10.3389/fcell.2020.00123.
49. Nowak KL, Chonchol M, Ikizler TA, et al. IL-1 Inhibition and Vascular Function in CKD. J Am Soc Nephrol 2017; 28: 971-980. 20160919. DOI: 10.1681/asn.2016040453.
50. Krensky AM and Ahn YT. Mechanisms of disease: regulation of RANTES (CCL5) in renal disease. Nat Clin Pract Nephrol 2007; 3: 164-170. DOI: 10.1038/ncpneph0418.
